Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Effect of pegbelfermin on NASH and fibrosis-related biomarkers and correlation with histological response in the FALCON 1 trial
Elizabeth A. Brown, Anne Minnich, Arun J. Sanyal, et al.
JHEP Reports (2023) Vol. 5, Iss. 4, pp. 100661-100661
Open Access | Times Cited: 28

Showing 1-25 of 28 citing articles:

Safety and efficacy of once-weekly efruxifermin versus placebo in non-alcoholic steatohepatitis (HARMONY): a multicentre, randomised, double-blind, placebo-controlled, phase 2b trial
Stephen A. Harrison, Juan P. Frías, Guy Neff, et al.
˜The œLancet. Gastroenterology & hepatology (2023) Vol. 8, Iss. 12, pp. 1080-1093
Closed Access | Times Cited: 91
Pegbelfermin in Patients With Nonalcoholic Steatohepatitis and Stage 3 Fibrosis (FALCON 1): A Randomized Phase 2b Study
Rohit Loomba, Arun J. Sanyal, Atsushi Nakajima, et al.
Clinical Gastroenterology and Hepatology (2023) Vol. 22, Iss. 1, pp. 102-112.e9
Open Access | Times Cited: 44
Steatotic Liver Disease: Pathophysiology and Emerging Pharmacotherapies
Michail Kokkorakis, Emir Muzurović, Špela Volčanšek, et al.
Pharmacological Reviews (2024) Vol. 76, Iss. 3, pp. 454-499
Open Access | Times Cited: 30
Gut-liver axis: Pathophysiological concepts and medical perspective in chronic liver diseases
Susana Rodrigues, Van der Merwe, Aleksander Krag, et al.
Seminars in Immunology (2024) Vol. 71, pp. 101859-101859
Open Access | Times Cited: 18
Current status and future perspectives of FGF21 analogues in clinical trials
Zara Siu Wa Chui, Qing Shen, Aimin Xu
Trends in Endocrinology and Metabolism (2024) Vol. 35, Iss. 5, pp. 371-384
Closed Access | Times Cited: 18
FGF-based drug discovery: advances and challenges
Gaozhi Chen, Lingfeng Chen, Xiaokun Li, et al.
Nature Reviews Drug Discovery (2025)
Closed Access | Times Cited: 4
Mitochondrial Stress and Mitokines: Therapeutic Perspectives for the Treatment of Metabolic Diseases
Benyuan Zhang, Joon Young Chang, Min Hee Lee, et al.
Diabetes & Metabolism Journal (2024) Vol. 48, Iss. 1, pp. 1-18
Open Access | Times Cited: 8
Hot and Cold Fibrosis: The Role of Serum Biomarkers to assess the Immune Mechanisms and ECM-Cell Interactions in Human Fibrosis
Andressa de Zawadzki, Diana Julie Leeming, Arun J. Sanyal, et al.
Journal of Hepatology (2025)
Open Access | Times Cited: 1
Overview and prospect of NAFLD: Significant roles of nutrients and dietary patterns in its progression or prevention
Tianyu Mao, Yiwen Sun, Xinyi Xu, et al.
Hepatology Communications (2023) Vol. 7, Iss. 10
Open Access | Times Cited: 17
Pharmacotherapeutic options for metabolic dysfunction-associated steatotic liver disease: where are we today?
Tobias Puengel, Frank Tacke
Expert Opinion on Pharmacotherapy (2024) Vol. 25, Iss. 9, pp. 1249-1263
Open Access | Times Cited: 7
Exercise Is Medicine for Nonalcoholic Fatty Liver Disease: Exploration of Putative Mechanisms
James Westley Heinle, Kara DiJoseph, Angelo Sabag, et al.
Nutrients (2023) Vol. 15, Iss. 11, pp. 2452-2452
Open Access | Times Cited: 14
Efruxifermin, an investigational treatment for fibrotic or cirrhotic nonalcoholic steatohepatitis (NASH)
Tobias Puengel, Frank Tacke
Expert Opinion on Investigational Drugs (2023) Vol. 32, Iss. 6, pp. 451-461
Closed Access | Times Cited: 14
Berberine Effects in Pre-Fibrotic Stages of Non-Alcoholic Fatty Liver Disease—Clinical and Pre-Clinical Overview and Systematic Review of the Literature
Florentina Ioniţă‐Radu, Cristina Patoni, Andreea Simona Nancoff, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 8, pp. 4201-4201
Open Access | Times Cited: 5
Crossing the Halfway Point: Aptamer-Based, Highly Multiplexed Assay for the Assessment of the Proteome
S. Kraemer, Daniel J. Schneider, Clare Paterson, et al.
Journal of Proteome Research (2024) Vol. 23, Iss. 11, pp. 4771-4788
Open Access | Times Cited: 5
Unlocking the Potential of Receptor-Based Approaches in Diabetes Treatment
Mohsina Patwekar, Faheem Patwekar, J. Pavan Kumar, et al.
BIO Integration (2025) Vol. 6, Iss. 1
Open Access
NASH Cirrhosis: A Systematic Review of Phase 2B Trials
Bipneet Singh, Sruthi Ramanan, Waryaam Singh, et al.
Open Journal of Gastroenterology (2025) Vol. 15, Iss. 04, pp. 126-148
Open Access
Emerging Drug Therapies for Metabolic Dysfunction-Associated Steatotic Liver Disease: A Glimpse into the Horizon
Jorge Arnold, Francisco Idalsoaga, Luis Antonio Díaz, et al.
Current Hepatology Reports (2024) Vol. 23, Iss. 1, pp. 204-219
Closed Access | Times Cited: 3
SomaLogic proteomics reveals new biomarkers and provides mechanistic, clinical insights into Acetyl coA Carboxylase (ACC) inhibition in Non-alcoholic Steatohepatitis (NASH)
Pitchumani Sivakumar, Michelle Saul, Douglas S. Robinson, et al.
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 3
Plasma proteomic profiles of pain subtypes in adolescents and young adults with endometriosis
Naoko Sasamoto, Long Ngo, Allison F. Vitonis, et al.
Human Reproduction (2023) Vol. 38, Iss. 8, pp. 1509-1519
Closed Access | Times Cited: 7
Pathophysiological Relationship between Type 2 Diabetes Mellitus and Metabolic Dysfunction-Associated Steatotic Liver Disease: Novel Therapeutic Approaches
Shifat-E Ferdous, Jessica M. Ferrell
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 16, pp. 8731-8731
Open Access | Times Cited: 2
Biomarkers of tissue remodelling are elevated in serum of COVID-19 patients who develop interstitial lung disease - an exploratory biomarker study
Helene W. Breisnes, Diana Julie Leeming, M.A. Karsdal, et al.
BMC Pulmonary Medicine (2024) Vol. 24, Iss. 1
Open Access | Times Cited: 1
Development of Zalfermin, a Long-Acting Proteolytically Stabilized FGF21 Analog
Kristian Sass‐Ørum, Tina M. Tagmose, Jørgen Olsen, et al.
Journal of Medicinal Chemistry (2024)
Open Access | Times Cited: 1
The role of nonmyocardial cells in the development of diabetic cardiomyopathy and the protective effects of FGF21: a current understanding
Tianyi Zhang, D.W. Jiang, Xiao Zhang, et al.
Cell Communication and Signaling (2024) Vol. 22, Iss. 1
Open Access | Times Cited: 1
Comparative Analysis of Resmetirom vs. FGF21 Analogs vs. GLP-1 Agonists in MASLD and MASH: Network Meta-Analysis of Clinical Trials
Hazem Ayesh, Azizullah Beran, Sajida Suhail, et al.
Biomedicines (2024) Vol. 12, Iss. 10, pp. 2328-2328
Open Access | Times Cited: 1
Non-alcoholic Steatohepatitis in Asians: Current Perspectives and Future Directions
Gourdas Choudhuri, Saumin Shah, Anand V. Kulkarni, et al.
Cureus (2023)
Open Access | Times Cited: 2
Page 1 - Next Page

Scroll to top